Our main objectives are to:
- make a major contribution to global efforts to eliminate hepatitis B
- work towards the World Health Organisation’s global viral hepatitis elimination strategy by addressing diagnosis, delivery of direct-acting antivirals, prevention and vaccine development.
Our research focuses on:
- developing and maintaining surveillance and clinical monitoring systems that help guide policy, prevention and care responses for hepatitis B in Australia and resource-constrained settings
- preventing new hepatitis B infections through behavioural and vaccination approaches
- trialling and implementing novel tools and strategies to deliver best-practice clinical care for hepatitis B
- enhancing collaborations and partnerships with clinical services, government, community organisations and affected populations to improve the transition of people through hepatitis B care
- implementing and advocating for harm reduction measures to minimise viral hepatitis transmission and prevent new infections in vulnerable populations
- developing point-of-care tests for viral hepatitis to determine the priority of treatment in resource-poor settings
- actively working with community groups to address stigma and discrimination.
Together with research organisations, governments, the community and affected populations, Burnet is working to help change the course of hepatitis B infection and its impact as a public health threat.
is the number of years of life lost to ill health, disability or early death resulting from hepatitis B that could be prevented if the cost-effective ways to improve the delivery and management of the HBV vaccine, as identified in a Burnet study, were to be implemented.
of all people with hepatitis B in Australia are clinically managed. Researchers working with Burnet are investigating why only a fraction of Australians with hepatitis B receive clinical management.
is the number of Australian women attending antenatal or post-partum hepatitis B care who were interviewed by researchers in a Burnet-supported qualitative study exploring their knowledge of hep B and experiences of related care.
Australians were asked about their feelings related to living with hepatitis B in a self-administered questionnaire as part of a Burnet-supported study investigating the concerns and anxieties among people living with chronic hepatitis B.
Working Groups
Burnet is an Australian-based medical research and public health institute and international non-government organisation that is working towards a more equitable world through better health.
Surveillance and Evaluation Group
Head: Professor Margaret Hellard. Manager: Mr Jason Asselin. This group manages HIV, Viral Hepatitis...
Modelling and Biostatistics Group
Head: Dr Nick Scott. Deputy Head: Dr Rachel Sacks-Davis. Modelling plays a critical role in translat...
Infectious Diseases Clinical Research
Co-Heads: Associate Professor Joseph Doyle and Professor Margaret Hellard. The Infectious Diseases C...